Mr. Soriot isn’t expected to leave immediately, but the company reportedly hired headhunters to draw up a list of potential internal candidates. The Times reports that potential candidates could include AstraZeneca’s senior executives Mene Pangalos and Ruud Dobber.
The news comes after the drugmaker suffered a setback with the failure of a big lung cancer trial in November.
Mr. Soriot had promised to achieve at least $40 billion in sales by 2023, and the cancer drug setback pushes that goal further out of reach.
More articles on pharmacy:
Florida adds CVS, Walgreens to opioid lawsuit
Pfizer to hike price of 41 drugs in January
Bristol-Myers Squibb to lay off 69 employees in Florida
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
